MA52935A - Composés inhibiteurs d'oga - Google Patents

Composés inhibiteurs d'oga

Info

Publication number
MA52935A
MA52935A MA052935A MA52935A MA52935A MA 52935 A MA52935 A MA 52935A MA 052935 A MA052935 A MA 052935A MA 52935 A MA52935 A MA 52935A MA 52935 A MA52935 A MA 52935A
Authority
MA
Morocco
Prior art keywords
inhibitor compounds
oga inhibitor
oga
compounds
inhibitor
Prior art date
Application number
MA052935A
Other languages
English (en)
Inventor
José Manuel Bartolomé-Nebreda
Susana Conde-Ceide
Francisca Delgado-Jiménez
Carlos Manuel Martinez-Viturro
Andrés Avelino Trabanco-Suárez
Ramiro Juan Antonio Vega
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA52935A publication Critical patent/MA52935A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA052935A 2018-06-20 2019-06-20 Composés inhibiteurs d'oga MA52935A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18382447 2018-06-20

Publications (1)

Publication Number Publication Date
MA52935A true MA52935A (fr) 2021-04-28

Family

ID=62784074

Family Applications (2)

Application Number Title Priority Date Filing Date
MA052935A MA52935A (fr) 2018-06-20 2019-06-20 Composés inhibiteurs d'oga
MA052934A MA52934A (fr) 2018-06-20 2019-06-20 Composés inhibiteurs de l'oga

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA052934A MA52934A (fr) 2018-06-20 2019-06-20 Composés inhibiteurs de l'oga

Country Status (9)

Country Link
US (2) US20210300943A1 (fr)
EP (2) EP3810594A1 (fr)
JP (2) JP2021528413A (fr)
CN (2) CN112334461A (fr)
AU (2) AU2019289968A1 (fr)
CA (2) CA3102462A1 (fr)
MA (2) MA52935A (fr)
TW (2) TW202012392A (fr)
WO (2) WO2019243527A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3585790A1 (fr) * 2017-02-27 2020-01-01 Janssen Pharmaceutica NV Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga
WO2021094312A1 (fr) * 2019-11-11 2021-05-20 Janssen Pharmaceutica Nv Composés inhibiteurs d'oga contenant de la pyrrolidine et de la bicyclohétéroaryle
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017003658B1 (pt) * 2014-08-28 2022-12-06 Asceneuron Sa Composto, mistura, método para inibição de uma glicosidase, e, composição farmacêutica
EP3478676A1 (fr) * 2016-06-29 2019-05-08 Orion Corporation Dérivés de benzodioxane et leur utilisation pharmaceutique
CN110300752A (zh) * 2016-12-16 2019-10-01 詹森药业有限公司 单环oga抑制剂化合物

Also Published As

Publication number Publication date
TW202016093A (zh) 2020-05-01
WO2019243526A1 (fr) 2019-12-26
JP2021527659A (ja) 2021-10-14
US20210300943A1 (en) 2021-09-30
AU2019289968A1 (en) 2020-12-17
US20210277015A1 (en) 2021-09-09
CA3102462A1 (fr) 2019-12-26
CN112334461A (zh) 2021-02-05
CA3102458A1 (fr) 2019-12-26
TW202012392A (zh) 2020-04-01
MA52934A (fr) 2021-04-28
CN112292377A (zh) 2021-01-29
AU2019289967A1 (en) 2020-12-17
EP3810594A1 (fr) 2021-04-28
WO2019243527A1 (fr) 2019-12-26
JP2021528413A (ja) 2021-10-21
EP3810593A1 (fr) 2021-04-28

Similar Documents

Publication Publication Date Title
MA52939A (fr) Composés inhibiteurs d'oga
MA52942A (fr) Composés inhibiteurs d'oga
MA47420A (fr) Composés inhibiteurs d'oga
IL292753A (en) Compounds
MA47575A (fr) Composés inhibiteurs d'oga monocyclique
EP3836923A4 (fr) Composés pyrrolo-dipyridine
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
EP3941898C0 (fr) Composés fongicides
MA52948A (fr) Composés
IL286833A (en) Compositions containing brazzein
EP3740487A4 (fr) Composés benzamide
MA51669A (fr) Composés
DK4083038T3 (da) Pyridazinylthiazolcarboxamidforbindelse
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
EP3464275A4 (fr) Composés inhibiteurs de l'egfr
MA53003A (fr) Composés
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA49006A (fr) Inhibiteurs d'ip6k
MA54521A (fr) Dérivés d'oxopyridine substitués
MA52946A (fr) Composés
EP3808747A4 (fr) Composé d'imidazopyridinone
EP4077318A4 (fr) Composés
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
EP3833342A4 (fr) Composés d'imidazotétrazine
LT3867247T (lt) Naujieji junginiai